<DOC>
	<DOC>NCT01022853</DOC>
	<brief_summary>The primary objective of the current study is to investigate the Maximum Tolerated Dose (MTD) in terms of safety and tolerability of BI 6727 in combination with fixed dose BIBF 1120, in patients with advanced or metastatic solid tumours.</brief_summary>
	<brief_title>Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Inclusion criteria: 1. Patients with confirmed diagnosis of advanced, non resectable and/or metastatic solid tumours, who have failed conventional treatment, and for whom no therapy of proven efficacy exists, or who are not amenable to established forms of treatment 2. Age &gt; or = 18 years 3. European Cooperative Oncology Group performance status &lt; or = 2 4. Written informed consent in accordance with International Conference on Harmonization Good Clinical Practice (ICHGCP) and local legislation 5. Recovery from Common Terminology Criteria for Adverse Events grade 24 therapyrelated toxicities from previous systemic anticancer therapies or radiotherapy (except alopecia) Exclusion criteria: 1. Serious illness or concomitant nononcological disease considered by the investigator to be incompatible with the trial 2. Known hypersensitivity to the trial drugs or their excipients 3. Treatment with any other investigational drug or participation in any other interventional trial within 28 days before first administration of trial drug (BIBF 1120) or concomitantly with this trial 4. Systemic anticancer therapy or radiotherapy within 28 days before start of therapy or concomitantly with this trial. The restriction does not apply to steroids and bisphosphonates 5. Active infectious disease infection or HIV I/II 6. Other malignancy currently requiring another anticancer therapy 7. Clinical evidence of symptomatic progressive brain or leptomeningeal disease during the past 6 months 8. Known inherited predisposition to bleeding or thrombosis 9. Radiographic evidence of cavitary or necrotic tumours 10. History of clinically significant haemoptysis within the past 3 months 11. Centrally located tumours with radiographic evidence (Computed Tomography or Magnetic Resonance Imaging) of local invasion of major blood vessels 12. Absolute Neutrophil Count (ANC) less than 1.5 x 1000000000/L 13. Platelets Count (PLT) less than 100 x 1000000000/L 14. Total bilirubin &gt; upper limit of normal (ULN) 15. Alaninaminotransferase (ALT) and/or Aspartateaminotransferase (AST) &gt;= 1.5 x ULN (in case of liver metastases: ALT and AST &gt;= 2.5 x ULN) 16. Serum creatinine &gt; 1.5 mg/dl 17. Major injuries and/or surgery or bone fracture within 28 days before first administration of trial drug (BIBF 1120), or planned surgical procedures during the trial period 18. Known history of clinically relevant QT prolongation (e.g. long QT syndrome) 19. History of severe haemorrhagic or thromboembolic event in the past 6 months (excluding central venous catheter thrombosis and peripheral deep vein thrombosis) 20. Therapeutic anticoagulation (except low dose heparin and/or heparin flush as needed for maintenance of an indwelling intravenous device) or antiplatelet therapy (except for chronic lowdose therapy with acetylsalicylic acid &lt; or = 325mg per day) 21. Active alcohol or drug abuse 22. Women and men who are sexually active and unwilling to use a medically acceptable method of contraception during the trial 23. Pregnancy or breastfeeding 24. Patients unable to comply with the protocol 25. Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>